Objective To investigate the clinical efficacy of Shufei Huatan Decoction in the treatment of children with chronic cough of phlegm-dampness accumulating in lung type and to observe its inflammatory regulatory effect.Methods A total of 116 children with chronic cough of phlegm-damp accumulating in lung type who were treated in the outpatient or inpatient departments of Dongguan Hospital,Guangzhou University of Chinese Medicine from February 2022 to February 2024 were randomly divided into the observation group and the control group,with 58 cases in each group.The control group was treated with conventional western medicine of antibiotics and antihistamines,while the observation group was treated with Shufei Huatan Decoction,a self-formulated Chinese medicine prescription.The course of treatment covered two weeks and then the patients were followed up for four weeks.Before and after treatment,the changes of scores of cough,expectoration,and pulmonary auscultation findings,levels of type 2 inflammatory factors of interleukin 4(IL-4)and total immunoglobulin E(IgE),and indicators of airway inflammation such as Eotaxin,fractional exhaled nitric oxide(FeNO)of the two groups were observed.After treatment,the clinical efficacy,the incidence of adverse reactions and the recurrence rate of the children in the two groups were compared.Results(1)After two weeks of treatment,the total effective rate of the observation group was 94.83%(55/58)and that of the control group was 86.21%(50/58),and the intergroup comparison(tested by chi-square test)showed that the therapeutic efficacy of the observation group was significantly superior to that of the control group(P<0.05).(2)After treatment,the scores of cough,expectoration,and pulmonary auscultation findings as well as their total scores in the two groups were decreased compared with those before treatment(P<0.05),and the decrease in the observation group was significantly superior to that in the control group(P<0.05).(3)After treatment,the levels of inflammatory factors of FeNO value and serum Eotaxin,IL-4,and total IgE of the two groups were decreased compared with those before treatment(P<0.05),and the decrease in the observation group was significantly superior to that in the control group(P<0.05).(4)The incidence of adverse reactions in the observation group was 8.62%(5/58)and that in the control group was 5.17%(3/58),and the intergroup comparison showed that the difference was not statistically significant(P>0.05).(5)The four-week follow-up showed that the recurrence rate in the observation group was 3.64%(2/55)and that in the control group was 10.00%(5/50),and the difference was not statistically significant between the two groups(P>0.05).Conclusion Shufei Huatan Decoction exerts certain efficacy in treating children with chronic cough of phlegm-damp accumulating in lung type,which is effective and safe on significantly improving children's clinical symptoms,reducing the release of inflammatory factors,and inhibiting the inflammatory reactions.

Objective To observe the effect of alteplase intra-arterial thrombolysis combined with continuous monitoring of transcranial Doppler (TCD) in patients with acute cerebral infarction. Methods Fifty-four patients with acute cerebral infarction were divided into TCD group and control group by random digits table method. The patients of 2 groups were given alteplase intra-arterial thrombolysis, and the patients of TCD groups were combined with continuous monitoring of TCD. The degree of clinical neurologic impairment was evaluated by National Institutes of Health stroke scale (NIHSS) and Barthel index (BI). The condition of vascular recanalization was evaluated by the change of blood flow signal of TCD. CT was performed within 1 d after thrombolysis to detect intracranial hemorrhage and other adverse reaction. The degree of clinical neurologic impairment, blood vessel recanalization rate after thrombolysis and recanalization time and incidence of intracranial hemorrhage and other adverse reaction were compared between 2 groups. Results There were no statistical difference in NIHSS score before thrombolysis and 1 h after thrombolysis between 2 groups (P>0.05). The NIHSS scores 7 and 30 d after thrombolysis in TCD group were significantly lower than those in control group:(8.1 ± 4.9) scores vs. (12.1 ± 4.2) scores and (6.9 ± 3.1) scores vs. (10.9 ± 3.9) scores, there were statistical differences (P<0.05). The BI scores 7 and 30 d after thrombolysis in TCD group were significantly higher than those in control group: (78.5 ± 13.8) scores vs. (60.8 ± 12.4) scores and (82.6 ± 13.5) scores vs. (63.2 ± 12.9) scores, and there were statistical differences (P<0.05). The blood vessel recanalization rate 24 h after thrombolysis in TCD group was significantly higher than that in control group: 70.4% (19/27) vs. 44.4% (12/27), the recanalization time after thrombolysis was significantly shorter than that in control group: (36.4 ± 9.5) min vs. (58.5 ± 12.4) min, and there were statistical differences (P<0.05). No adverse reaction like intracranial hemorrhage and so on was found by CT detection within 1 d after thrombolysis in the 2 groups. Conclusions Alteplase intra-arterial thrombolysis combined with continuous monitoring of TCD in acute cerebral infarction has good curative effect, and no obvious adverse reaction.